Author

Beatriz Paredes-Moreno

Observed names: Beatriz Paredes Moreno, Paredes Moreno, Beatriz, Paredes-Moreno, Beatriz

ORCID: 0000-0003-2034-6773

Observed ORCID: 0000-0003-2034-6773

OpenAlex ID: A5085620054

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

2022 · María Eugenia Toledo-Romaní, Mayra García-Carmenate, et al. · The Lancet Regional Health - Americas · 71

PDF

Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.

2012 · Mayra Ramos-Suzarte, Patricia Lorenzo-Luaces, et al. · Cancer Biology & Therapy · 71

PDF

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

2022 · María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, et al. · Vaccine · 38

PDF

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

2022 · Sonia Pérez-Rodríguez, Meiby de la Caridad Rodríguez-González, et al. · Vaccine · 37

PDF

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · International Journal of Infectious Diseases · 33

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · Med · 30

PDF

Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I

2018 · Carlos P. Dotres Martínez, Nivaldo Linares-Pérez, et al. · Vaccine · 12

PDF

Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children

2023 · Rocmira Perez-Nicado, Chiara Massa, et al. · Vaccines · 8

PDF

Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · medRxiv · 5

PDF

La nueva vacuna cubana antineumocócica, de las evidencias científicas disponibles, a la estrategia de evaluación clínica y de impacto

2017 · Nivaldo Linares-Pérez, María Eugenia Toledo-Romaní, et al. · Revista cubana de pediatría · 4

Seroprevalence of Oropouche virus following the 2024–2025 outbreak in Cuba

2026 · Dagmar García-Rivera, Carlo Fischer, et al. · Nature Health · 3

Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

2024 · Dagmar García-Rivera, Rinaldo Puga-Gómez, et al. · Vaccine X · 2

Safety and Cross-Neutralizing Immunity Against SARS-CoV-2 Omicron Sub-Variant After a Booster Dose with SOBERANA® Plus in Children and Adolescents

2025 · Dagmar García-Rivera, Meiby Rodríguez-González, et al. · Vaccines · 1

PDF

Seguridad, inmunogenicidad y eficacia de las vacunas SOBERANA ® 02 y SOBERANA® Plus en población pediátrica

2025 · Puga-Gómez, Rinaldo, Fonseca Hernández, Mercedes, et al. · Anales de la Academia de Ciencias de Cuba

PDF

Evaluación preclínica y clínica de SOBERANA® 01. Candidato vacunal contra la COVID-19

2023 · Climent Ruiz, Yanet, Santana Mederos, Darielys, et al. · Anales de la Academia de Ciencias de Cuba

PDF

Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial

2022 · Maria Eugenia-Toledo-Romani, Mayra García Carmenate, et al. · SSRN Electronic Journal

Works count: 17

Citation count: 315

H-index: 8

I10-index: 7